SkinBioTherapeutics
SkinBioTherapeutics plc is a UK life sciences company that develops and commercialises microbiome-based skincare products, oral supplements, and licensed ingredients, serving consumers, NHS prescribers, and B2B partners through Dermatonics, AxisBiotix, and Bio-Tech Solutions.
- Company typePublic
- Founded2016
- HeadquartersMacclesfield, United Kingdom
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What SkinBioTherapeutics does
SkinBioTherapeutics plc is a UK-listed life sciences company focused on advancing skin health through both topical and oral interventions. Founded in 2016 as a spin-out from the University of Manchester's translational dermatology team, the company has assembled a portfolio spanning consumer skincare, prescription dermatology, oral supplements, and IP licensing. Its core technology is the SkinBiotix platform — a microbiome-based system derived from probiotic bacteria lysates — which underpins both internal product development and an out-licensing arrangement with Croda International for the Zenakine neurocosmetic ingredient.
The group operates through three operating subsidiaries plus an IP licensing business. Dermatonics (acquired January 2024) provides clinically validated topical foot and hand care products sold to NHS prescribers and through Boots, Superdrug, and Amazon. AxisBiotix Limited sells oral probiotic supplements (SkinCalm, SkinClear) targeting the gut-skin axis for inflammatory skin conditions. Bio-Tech Solutions Limited (acquired 2025) provides in-house contract manufacturing and packaging services to NHS, veterinary, and nutraceutical customers. The Croda partnership monetises SkinBiotix IP via tiered royalties on global sales of the Zenakine ingredient to Croda's >12,000 personal care customers.
Revenue in FY2025 reached approximately $4.6M, up from $1.2M in FY2024 and $74K in FY2022, reflecting the impact of the Dermatonics and Bio-Tech Solutions acquisitions. EBITDA has remained negative throughout the reported period, indicating the company is in scale-build mode rather than profitability. The company has undergone significant leadership transition in early 2026, with CEO Stuart Ashman's resignation and Rachel Parsonage's appointment as Interim CEO, alongside an AIM trading suspension in April 2026 and subsequent restoration in June 2026.
SkinBioTherapeutics firmographics
Firmographics- Name
- SkinBioTherapeutics
- Legal name
- SkinBioTherapeutics PLC
- Website
- https://skinbiotherapeutics.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SkinBioTherapeutics plc is a UK life sciences company that develops and commercialises microbiome-based skincare products, oral supplements, and licensed ingredients, serving consumers, NHS prescribers, and B2B partners through Dermatonics, AxisBiotix, and Bio-Tech Solutions.
- Ownership category
- akta.pro rank
SkinBioTherapeutics industry classification
Industry- Product category
- Skincare and Dermatological Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
- akta.pro secondary industries
- Sensitive Skin & Barrier Repair (CRABAAAG), Dermatology Specialty Pharmaceuticals (HLAIACAL), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where SkinBioTherapeutics is headquartered
LocationHeadquarters
- HQ city
- Macclesfield
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
SkinBioTherapeutics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D
Revenue model
- Product Sales - Dermatonics: Direct and indirect sales of Dermatonics dermatological products including professional range (NHS, podiatrists) and retail range (Boots, Superdrug, Amazon, direct online). Products address foot and hand care conditions including anhydrotic and fissured skin, calluses, hyperkeratosis, and dry or compromised skin.
- Product Sales - AxisBiotix: Direct-to-consumer sales of AxisBiotix food supplements (SkinCalm and SkinClear) via AxisBiotix website, Amazon, and selected Superdrug stores. Targets skin health through gut-skin axis for inflammatory skin conditions.
- IP Licensing Royalties: Tiered royalties from outlicensing of SkinBiotix intellectual property. Commercial agreement with Croda for Zenakine ingredient with royalty revenues recognised as confirmed sales data received.
- Contract Manufacturing (Bio-Tech Solutions): Contract manufacturing and packaging services for health, hygiene, and personal care products. Services include labelling, R&D product support, and full-service contract manufacturing for NHS, private institutions, medical wholesalers, and veterinary product distributors.
Go-to-market motion4 records
Distribution channels7 records
Marketing channels7 records
SkinBioTherapeutics product offering
Product offeringCore offering
SkinBioTherapeutics is a life sciences company that develops and commercialises products supporting skin health from both outside-in (topical) and inside-out (oral supplement) perspectives. Its core offerings include the Dermatonics range of clinically validated foot and hand care products, the AxisBiotix range of probiotic food supplements targeting the gut-skin axis, and contract manufacturing services through Bio-Tech Solutions, supported by proprietary SkinBiotix® microbiome platform technology out-licensed to Croda International as the Zenakine™ neuroactive ingredient.
Product overview
SkinBioTherapeutics is a life sciences company operating as a platform-plus-subsidiaries model. The group develops products addressing skin health from both outside-in (topical) and inside-out (oral) perspectives. Core portfolio includes: Dermatonics (clinically validated topical foot/hand care brand acquired in 2025), AxisBiotix (oral probiotic supplements targeting the gut-skin axis), Bio-Tech Solutions (in-house manufacturing division for contract manufacturing), SkinBiotix (proprietary microbiome platform technology licensed to Croda for Zenakine ingredient), and Zenakine (neurocosmetic ingredient commercialized through Croda partnership).
Differentiator
Problem solved
Functional benefit
Brands
- Dermatonics: A clinically validated range of topical foot and hand care products, trusted by consumers, the NHS and specialist podiatrists across UK and US markets. Includes professional range prescribed by GPs, podiatrists, dermatologists, and nurses, and cosmetic retail range Green & Gold.
- AxisBiotix
- Bio-Tech Solutions
- SkinBiotix
- Zenakine
Products and services
- Dermatonics A clinically validated range of topical foot and hand care products trusted by consumers, the NHS and specialist podiatrists across UK and US markets. Includes the professional range prescribed by GPs, podiatrists, dermatologists, and nurses (listed on UK Drug Tariff) and the cosmetic retail range Green & Gold. Products address anhydrotic and fissured skin, calluses, hyperkeratosis, and dry or compromised skin, including clinical evidence of up to 96% success rate in treating callus in high-risk NHS patients within 14 days.
- AxisBiotix An oral food supplement supporting skin health from within through the gut-skin axis, containing four live bacterial strains (Bifidobacterium animalis, Levilactobacillus brevis, Limosilactobacillus reuteri, and Lactococcus lactis cremoris) protected by Probioact® technology. Currently includes SkinCalm and SkinClear product lines targeting inflammatory skin conditions including psoriasis and acne. The BRIGHT Study showed over 70% of participants reported overall improvement across four areas of skin health within 8 weeks. Sold direct via AxisBiotix website, Amazon, and selected Superdrug stores.
- Bio-Tech Solutions An in-house contract manufacturing and packaging division specialising in health, hygiene and personal care products. Services include labelling, R&D product support, and full-service contract manufacturing for NHS, private healthcare institutions, medical wholesalers, and veterinary product distributors. Led by Managing Director Tim Wakeley with over 33 years of food manufacturing experience.
- Zenakine™ A biotech-based neuroactive ingredient developed with Croda International (Sederma) and based on SkinBiotix IP, targeting the effects of stress on skin by supporting natural response to stress and enhancing melatonin production. Fully biodegradable and compliant with COSMOS and RSPO standards. Awarded Novelty Merit at the 2026 C&T Allē beauty awards. Sold through Croda's global Personal Care portfolio spanning over 12,000 customers.
Quantifiable outcome
- Up to 96% of high-risk NHS patients had callus successfully treated within 14 days using Dermatonics Once Heel Balm
- +1 more outcomes
Companies that use SkinBioTherapeutics
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
SkinBioTherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SkinBioTherapeutics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Croda International Plc (Zenakine)coreZenakine launched at in-cosmetics Global 2025 as world-first neurocosmetic ingredient based on SkinBiotix IP. Fully biodegradable and compliant with COSMOS and RSPO standards. Croda leveraging Zenakine as addition to their premium beauty actives portfolio.
- Winclove Probiotics B.V.coreDevelopment agreement with Winclove Probiotics for joint development and subsequent commercialisation of probiotic food supplement AxisBiotix targeting psoriasis. Winclove provides Probioact® technology to protect bacterial strains through manufacturing and gastrointestinal transit. Winclove responsible for formulation and manufacture. Development agreement period of three years with potential extension.
- Croda International PlccoreCommercial agreement with Croda International for development and commercialisation of active skincare ingredients using SkinBiotix technology. Sederma, part of Croda, responsible for development, manufacturing and commercialisation. Zenakine (based on SkinBiotix IP) launched at in-cosmetics Global April 2025. SkinBioTherapeutics receives tiered royalties based on global sales revenues.
- University of ManchestercoreFoundational research partnership where science underpinning SkinBioTherapeutics' oral ingredient development originated. Translational dermatology team discoveries inform gut-skin axis and microbiome-derived actives approach. Company spun out from University in March 2016 based on these discoveries.
- Vigo ConsultingminorFinancial PR advisory providing investor relations communications support. Office at 78-79 New Bond Street, London W1S 1RZ.
- Share Registrars LimitedminorShare registrar services for SkinBioTherapeutics plc managing shareholder records and administrative functions. Office at The Courtyard, 17 West Street, Farnham GU9 7DR.
- Penningtons Manches CooperminorLegal adviser to the company providing legal counsel on corporate and commercial matters. Office at 125 Wood Street, London EC2V 7AW.
Scale indicators9 records
Recent moves9 records
Expansion highlights5 records
SkinBioTherapeutics competitors and assessment
Company assessmentEmerging players
- Codex Labs: Microbiome-focused skincare company combining topical products with probiotic supplements targeting skin conditions. Directly comparable as a smaller, science-led skin microbiome brand competing in the same dermatology-adjacent space.
- AOBiome: Clinical-stage microbiome company developing live bacterial therapeutics for skin conditions including eczema and acne. Comparable as a science-led microbiome company targeting skin health through the skin and gut microbiome.
Broad incumbents
- Haleon: Global consumer health company selling OTC dermatology and skincare brands through pharmacy and supermarket channels. Comparable scale player with significant Boots/Superdrug retail presence in the UK.
- DSM-Firmenich: Global specialty ingredients and nutrition company with skin health, microbiome and nutritional supplement offerings. Comparable as a large-scale ingredient supplier and topical/oral skin health player.
- Sederma (Croda): Croda's specialty ingredients subsidiary commercializing bioactive cosmetic ingredients including Zenakine. Comparable as the channel partner for SkinBioTherapeutics' IP licensing and a peer in neurocosmetic and microbiome-based active ingredients.
- Symrise: Global supplier of cosmetic actives, fragrances and nutrition ingredients including microbiome-derived ingredients. Comparable as a peer in neurocosmetic and biotech-based active ingredients.
- Galderma: Global dermatology-focused company with a broad prescription and consumer skincare portfolio. Directly comparable as a dermatology specialist commercializing clinically validated skin health products, though at significantly larger scale.
Direct peers
- Gallinée: Microbiome-focused skincare brand developing products that support the skin microbiome and gut-skin axis. Comparable model combining probiotic supplements with topical skincare for skin conditions.
- BioGaia: Swedish probiotic company developing clinically documented probiotic strains for health applications, including skin health through the gut-skin axis. Closely comparable to AxisBiotix's probiotic supplement model with documented clinical outcomes.
- Winclove Probiotics: Dutch probiotic company providing Probioact technology and AxisBiotix formulation/manufacturing. Directly comparable as a probiotic partner and formulation peer serving the gut-skin axis health market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SkinBioTherapeutics social profiles
Digital presenceSkinBioTherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
SkinBioTherapeutics leadership team
Management profileNumber of profiles
Profiles9 records
SkinBioTherapeutics subsidiaries and ownership
Company hierarchySubsidiaries3 records
SkinBioTherapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SkinBioTherapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SkinBioTherapeutics
What does SkinBioTherapeutics do?
SkinBioTherapeutics is a life sciences company that develops and commercialises products supporting skin health from both outside-in (topical) and inside-out (oral supplement) perspectives. Its core offerings include the Dermatonics range of clinically validated foot and hand care products, the AxisBiotix range of probiotic food supplements targeting the gut-skin axis, and contract manufacturing services through Bio-Tech Solutions, supported by proprietary SkinBiotix® microbiome platform technology out-licensed to Croda International as the Zenakine™ neuroactive ingredient.
Is SkinBioTherapeutics a public or private company?
SkinBioTherapeutics is a public company. It is classified as public and is currently operating.
When was SkinBioTherapeutics founded?
SkinBioTherapeutics was founded in 2016. It employs 1 to 10 people.
Where is SkinBioTherapeutics based?
SkinBioTherapeutics is headquartered in Macclesfield, United Kingdom, in the Europe region.
How does SkinBioTherapeutics make money?
Four revenue lines are on record. Product Sales - Dermatonics are the primary driver. The others are product Sales - AxisBiotix, IP Licensing Royalties and contract Manufacturing (Bio-Tech Solutions).
Who are SkinBioTherapeutics's main competitors?
Emerging players on record are Codex Labs and AOBiome. Broad incumbents are Haleon, DSM-Firmenich, Sederma (Croda), Symrise and Galderma. Direct peers are Gallinée, BioGaia and Winclove Probiotics.
Does SkinBioTherapeutics have an API?
No public API is recorded for SkinBioTherapeutics.
What industry is SkinBioTherapeutics in?
SkinBioTherapeutics's product category is Skincare and Dermatological Products. Its primary akta.pro industry code is CRABAAAF, Dermocosmetics & Medical-Grade Skincare, with a secondary code of CRABAAAG, Sensitive Skin & Barrier Repair. Its NAICS code is 325414 and its SIC code is 2844.